Aripiprazole - Abilify

Noise as in natural fluctuation.
I disagree here. We've seen huge improvements in patients who had been severe or very severe for years. Generally, there aren't many fluctuations in these cases. They're extremely rare.


I know, and that's why I'm not completely pessimistic, as for most other trials. I also know from experience that it can be a very activating drug.

But if you look at the data from this trial...we've seen drugs that failed in controlled trials but looked more promising than that in their open-label trials.
Are you referring to the only LDA study conducted by Bonilla, which has been widely criticized for the way it was carried out?
Bonilla's 2021 study was retrospective, with no randomization, placebo group, or double-blinding. Doses ranged from 0.2 to 2 mg/day, with no proper investigation of the optimal dose. Finally, follow-up periods varied considerably (from less than one month to 17 months), with no rigorous assessment of a potential loss of effectiveness over time.

We've had five studies on LDN and just one poorly conducted study on LDA, even though LDA is the only treatment for which so many patients have reported almost miraculous improvements, particularly among severe and very severe patients, whose symptoms generally don't fluctuate.

Personally, I thought immunoadsorption/IVIG helped me get rid of my terrible PEM. We have accounts of massive improvements with this, as well. But in the meantime, we have controlled trials and there's nothing.
Correlation does not imply causation. I don't see why IVIG would work. I've tried it myself, with no benefit whatsoever.

On the other hand, LDA would be more consistent with the DecodeME findings, which point towards neurons.

We may have to wait a long time.

The limitations of this study, in my opinion:
The study excludes very severe patients and some severe patients, even though they are among those reporting spectacular improvements with LDA.
The 1 mg dose is relatively high, with no real attempt to identify the minimum effective dose.
Finally, eight weeks of treatment won't be enough to assess a potential loss of effectiveness after several months.

And you're absolutely right about the ridiculous timelines... Late 2028... It's absurd
I'm not 'automatically dismissing'. I'm being skeptical based on unconvincing data from a clinical trial with 50 participants where Abilify didn't reach statistical significance in 9/10 outcome measures.
As I mentioned earlier, this study has its limitations.
Isn't it worth trying again? I think the recent discoveries justify new, well-designed trials of a range of drugs acting on neurotransmitters. That would be more worthwhile than studying LDN or curcumin, or even rapamycin or Mestinon.
 
But I also want to add something that goes against my own argument, because we have to be honest: this drug can also make severe patients worse.

A friend of mine tried it, just two drops, and his condition deteriorated, with terrible stomach pain. Yet in my case, it actually relieved my gastroparesis.

There are also other reports of patients getting worse, experiencing insomnia (which I'm currently dealing with myself at 0.4 mg), mood disturbances, and so on.

Even at very low doses, this drug can be difficult to tolerate.
 
I disagree here. We've seen huge improvements in patients who had been severe or very severe for years. Generally, there aren't many fluctuations in these cases. They're extremely rare.
Here's a severe (maybe one the lighter end), sick for many years, and credits her improvement to LDN.

Here's a severe one that recovered with IVIG.

Im the uncontrolled IA trials, there were multiple people who may count as severe and improved quite drastically.

These anecdotes are not exclusive to LDA.

Are you referring to the only LDA study conducted by Bonilla, which has been widely criticized for the way it was carried out?
I was referring to the 2026 Bonilla study that I linked in my initial post which, admittedly, is about Long Covid, but also tracked PEM.
Have you looked at the diagrams?

Bonilla's 2021 study was retrospective, with no randomization, placebo group, or double-blinding. Doses ranged from 0.2 to 2 mg/day, with no proper investigation of the optimal dose. Finally, follow-up periods varied considerably (from less than one month to 17 months), with no rigorous assessment of a potential loss of effectiveness over time.
Right. And except for the dosing, these things favor positive outcomes. So if a study has no blinding but still doesn't produce convincing improvements, that is an indication against an effective drug.

If an observational study already fails to show efficacy, you don't need a randomized controlled follow-up to prove that there's nothing.

But as you mention, there's the issue with the dosing, and the 2021 study did show efficacy.

I'm not arguing we should forget about LDA and not do a controlled trial.
I'm saying the data we have so far does not inspire confidence that LDA is truly working (well).

LDA is the only treatment for which so many patients have reported almost miraculous improvements, particularly among severe and very severe patients, whose symptoms generally don't fluctuate.
I don't think this is true, see above.
Correlation does not imply causation.
Exactly! That goes for all anectodes, including LDA.
I don't see why IVIG would work. I've tried it myself, with no benefit whatsoever.
The point I was making, is that positive anecdotes exist for such things that have been shown not to work.
Isn't it worth trying again?
Of course it is. I never argued against doing a proper study.
 
Here's a severe (maybe one the lighter end), sick for many years, and credits her improvement to LDN.

Here's a severe one that recovered with IVIG.

Im the uncontrolled IA trials, there were multiple people who may count as severe and improved quite drastically.

These anecdotes are not exclusive to LDA.
That's really the only point we disagree on in the end. But it's not a big deal.

There are hundreds of reports of spectacular improvements with LDA (anecdotal evidence, admittedly, bur it's huge compared with others drugs), including among very severe patients, not just severe ones. I'm talking about people who have been bedridden for years, unable to tolerate any stimulation.
Of course, we can question these reports by attributing the improvements to natural fluctuations, but we know that wouldn't be entirely honest, because someone who has been bedridden for years is very unlikely to experience major spontaneous improvements without treatment.

Something is happening with this drug. It clearly seems to have beneficial effects on some of the sickest patients. The question now is why.

Even Professor Edwards, who is usually extremely cautious about patient testimonials, believes this deserves further investigation. The DecodeME findings also lend support to this hypothesis.

We need a properly designed clinical trial (unfortunately, Bonilla's 2021 study has many methodological shortcomings) to understand why this drug seems to work for some patients.

That said, we know the problems: potentially terrible side effects for severe and very severe patients, a reported loss of effectiveness in 75–80% of cases (according to a poll in an excellent Facebook group that has unfortunately been deleted), and, of course, the lack of well-designed clinical studies on the subject. We should have at least three by now.

Anyway, I think we agree on what matters most.
 
I've just read that LDA has an off-label use in lowering prolactin levels. This may/may not be relevant/discussed previously.

If I could get hold of LDA, I'd certainly try it given one of my few abnormal tests over the last decade has been several blood results showing idiopathic hyperprolactinemia.
 
Back
Top Bottom